A TITAN step forward: apalutamide for metastatic castration-sensitive prostate cancer

被引：6
|
作者：
Kwon, Daniel Hyuck-Min [1 ,2 ]
Friedlander, Terence [1 ,2 ]
机构：
[1] Univ Calif San Francisco, Dept Med, Div Hematol & Oncol, San Francisco, CA 94143 USA
[2] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA
来源：
ANNALS OF TRANSLATIONAL MEDICINE | 2019年 / 7卷
关键词：
ABIRATERONE; THERAPY;
D O I：
10.21037/atm.2019.09.21
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [21] Apalutamide (APA) for metastatic castration-sensitive prostate cancer (mCSPC) in TITAN: Outcomes in patients (pts) with low- and high-risk disease
    Ozguroglu, Mustafa
    Chowdhury, Simon
    Bjartell, Anders
    Uemura, Hirotsugu
    Chung, Byung Ha
    Agarwal, Neeraj
    Merseburger, Axel Stuart
    Soto, Alvaro Juarez
    Lopez-Gitlitz, Angela
    Bhaumik, Amitabha
    Larsen, Julie S.
    McCarthy, Sharon Anne
    Chi, Kim N.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [22] Efficacy and safety exposure–response relationships of apalutamide in patients with metastatic castration-sensitive prostate cancer: results from the phase 3 TITAN study
    Huybrecht T’jollyn
    Oliver Ackaert
    Caly Chien
    Angela Lopez-Gitlitz
    Sharon McCarthy
    Carlos Perez Ruixo
    Lawrence Karsh
    Kim Chi
    Simon Chowdhury
    Juan-Jose Perez Ruixo
    Neeraj Agarwal
    Cancer Chemotherapy and Pharmacology, 2022, 89 : 629 - 641
  • [23] A cost-utility analysis of apalutamide for the treatment of patients with metastatic castration-sensitive prostate cancer (mCSPC).
    Parmar, Ambika
    Timilshina, Narhari
    Emmenegger, Urban
    Alibhai, Shabbir M. H.
    Smoragiewicz, Martin
    Sander, Beate
    Chan, Kelvin K.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [24] Metastatic castration-sensitive prostate cancer: Abiraterone, docetaxel, or ...
    Barata, Pedro C.
    Sartor, A. Oliver
    CANCER, 2019, 125 (11) : 1777 - 1788
  • [25] Charting a course in metastatic castration-sensitive prostate cancer
    Ravi A. Madan
    William L. Dahut
    Nature Reviews Urology, 2015, 12 : 368 - 369
  • [26] The evolving options in metastatic castration-sensitive prostate cancer
    Hamilou, Zineb
    CURRENT OPINION IN SUPPORTIVE AND PALLIATIVE CARE, 2020, 14 (03) : 270 - 275
  • [27] Charting a course in metastatic castration-sensitive prostate cancer
    Madan, Ravi A.
    Dahut, William L.
    NATURE REVIEWS UROLOGY, 2015, 12 (07) : 368 - 369
  • [28] Treatment Options in Metastatic Castration-Sensitive Prostate Cancer
    Choudhury, Atish D.
    ONCOLOGY-NEW YORK, 2022, 36 (03): : 184 - 185
  • [29] Apalutamide or enzalutamide in castration-sensitive prostate cancer: a number needed to treat analysis
    Santoni, Matteo
    Massari, Francesco
    Rizzo, Alessandro
    Mollica, Veronica
    Cimadamore, Alessia
    Montironi, Rodolfo
    Battelli, Nicola
    TUMORI JOURNAL, 2023, 109 (02): : 157 - 163
  • [30] Molecular signatures associated with long-term response to apalutamide (APA) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) in TITAN.
    Lucas, Justin
    Agarwal, Neeraj
    Feng, Felix
    Aguilar-Bonavides, Clemente
    Thomas, Shibu
    Gormley, Michael
    Mundle, Suneel
    Brookman-May, Sabine
    McCarthy, Sharon A.
    Bjartell, Anders
    Uemura, Hirotsugu
    Chowdhury, Simon
    Chi, Kim N.
    CANCER RESEARCH, 2021, 81 (13)
12345